SynthesisJournal for immunotherapy of cancer2019

First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy.

Yixin Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.